Seattle Genetics

01.03.2023 • News

Pfizer in Talks to Take Cancer Biotech Seagen

Pfizer is in the early stage of talks to acquire Seagen (formerly Seattle Genetics), a US biotech focused on developing treatments for cancer, according to a report in the Wall Street Journal that cited people familiar with the matter. The purchase price could potentially be more than $30 billion.

18.07.2012 • News

Surge in Biotech Deals to Unlock Big Investor Profits

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Digitalization in the Chemical Industry

Evonik Operations GmbH (Hanau)

Biobased Feedstocks as a Roadmap to Defossilization

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.